An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2015
Price : $35 *
At a glance
- Drugs CEP 37440 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 08 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Mar 2014 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 20 Aug 2013 New trial record